In fact, assessments of the presence of internal tandem duplications in the FLT3 receptor gene (FLT3-ITD) [8] and mutations in the NPM1 gene [4] are currently routine practices in guiding therapeutic decisions in AML patients with a normal karyotype [9]. This evidence concerns the gene FLT3 and acute myeloid leukemia.